

For immediate release

25 September 2025



**Porvair plc**  
**("Porvair" or the "Group" or the "Company")**

**Board Changes**

**Lisa Anson**

Lisa Anson has been appointed as Non-Executive Director of the Company with effect from 1 October 2025.

Lisa is currently Chief Executive Officer of Redx Pharma limited, a UK based, privately held clinical-stage biotech business; a position she held when Redx was publicly listed on AIM. In addition, she is a Supervisory Board Member for Apoplex Medical Technologies GmbH, a private German company and is an elected Board Member of the UK BioIndustry Association (BIA). She was previously a Board Member and then Chair at the Association of the British Pharmaceutical Industry (ABPI).

Lisa's career spans almost 30 years in the pharmaceutical and Biotech industry including more than twenty years at AstraZeneca Plc. She has extensive global leadership and commercial experience, including several USA based roles and most recently was Country President for the UK and Ireland.

On appointment, Lisa will join the Audit Committee, Remuneration Committee and Nomination Committee of Porvair.

Porvair confirms that there are no further matters in relation to Lisa Anson's appointment to be disclosed pursuant to the requirements of paragraph 6.4.8 of the Listing Rules of the UK Listing Authority.

**Sally Martin**

Having completed 9 years as a Non-Executive Director at Porvair, Sally Martin will retire from the Board on 4 November 2025.

**Sheena Mackay**

Following Sally's retirement, Sheena Mackay will be appointed Senior Independent Director of the Board and the Non-Executive Director responsible for employee engagement, in addition to her role as Chair of the Remuneration Committee.

For further information, please contact:

**Porvair plc**  
Hooman Caman Jawi, Chief Executive Officer  
Andrew Douglass, Group Company Secretary

+44 (0)1553 765 500

**Burson Buchanan**  
Charles Ryland / Stephanie Whitmore

+44 (0)207 466 5000

Notes to editors

**Porvair plc**

Porvair is a group of specialist filtration, laboratory and environmental technology businesses. Its businesses design and manufacture a range of bespoke consumable filtration products that are used in a range of niche filtration markets. It operates in three divisions: Aerospace & Industrial; Laboratory; and Metal Melt Quality.

information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAEZLFLEKLZBBF